SHEFFIELD, ENGLAND — Rinri Therapeutics, a biotechnology company developing a novel stem cell therapy to restore hearing, today announces that it has raised a total of £10 million) from existing investors Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures and BioCity alongside the UK Government Future Fund.
The proceeds will support the development of the company’s novel stem cell therapy to reverse sensorineural hearing loss (SNHL).
For all general, membership and technical enquiries, please contact:
+44 (0) 118 954 2175
PO Box 3251